Critical Comparison: Standard Diversified Inc Class A (NYSEAMERICAN) (SDI) versus Pharming Group (PHGUF)

Standard Diversified Inc Class A (NYSEAMERICAN) (NYSE:SDI) and Pharming Group (OTCMKTS:PHGUF) are both small-cap multi-sector conglomerates companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, earnings, risk, analyst recommendations and institutional ownership.

Earnings & Valuation

This table compares Standard Diversified Inc Class A (NYSEAMERICAN) and Pharming Group’s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Standard Diversified Inc Class A (NYSEAMERICAN) $285.80 million 0.88 $10.37 million N/A N/A
Pharming Group $101.24 million 6.29 -$90.37 million ($0.18) -6.11

Standard Diversified Inc Class A (NYSEAMERICAN) has higher revenue and earnings than Pharming Group.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Standard Diversified Inc Class A (NYSEAMERICAN) and Pharming Group, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Standard Diversified Inc Class A (NYSEAMERICAN) 0 0 0 0 N/A
Pharming Group 0 0 1 0 3.00

Profitability

This table compares Standard Diversified Inc Class A (NYSEAMERICAN) and Pharming Group’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Standard Diversified Inc Class A (NYSEAMERICAN) 2.40% 18.09% 3.83%
Pharming Group -36.30% -176.01% -26.20%

Insider & Institutional Ownership

44.5% of Standard Diversified Inc Class A (NYSEAMERICAN) shares are held by institutional investors. 10.2% of Standard Diversified Inc Class A (NYSEAMERICAN) shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Volatility and Risk

Standard Diversified Inc Class A (NYSEAMERICAN) has a beta of -0.45, indicating that its stock price is 145% less volatile than the S&P 500. Comparatively, Pharming Group has a beta of 2.81, indicating that its stock price is 181% more volatile than the S&P 500.

Summary

Standard Diversified Inc Class A (NYSEAMERICAN) beats Pharming Group on 7 of the 10 factors compared between the two stocks.

About Standard Diversified Inc Class A (NYSEAMERICAN)

Standard Diversified, Inc. operates as shell company, which intends to identify new business and investment opportunities. The company was founded by Martha C. Reider and Richard C. Birkmeyer in 1990 and is headquartered in Mineola, NY.

About Pharming Group

Pharming Group N.V., a specialty pharmaceutical company, develops and produces human therapeutic proteins for the treatment of rare diseases and unmet medical needs. The company's lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the treatment of angioedema attacks in patients with acute hereditary angioedema (HAE) in Europe, the United States, Israel, European Union countries, Norway, Iceland, and Liechtenstein. It also engages in the development of recombinant human C1 inhibitor for treating HAE attacks; and recombinant human factor VIII (rhFVIII), a natural human blood clotting factor for treating haemophilia A. The company has a strategic collaboration with Shanghai Institute of Pharmaceutical Industry for the development, manufacture, and commercialization of new products based on the Pharming technology platform; and a partnership agreement with the China State Institute of Pharmaceutical Industry for the development of rhFVIII for the treatment of Haemophilia A. Pharming Group N.V. is headquartered in Leiden, the Netherlands.

Receive News & Ratings for Standard Diversified Inc Class A (NYSEAMERICAN) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Standard Diversified Inc Class A (NYSEAMERICAN) and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply